Report Detail
Global Ankylosing Spondylitis Drug Market Insights, Forecast to 2025
- RnM2700223 |
- 11 June, 2019 |
- Global |
- 114 Pages |
- QYResearch |
- Pharma & Healthcare
Ankylosing spondylitis is a form of chronic inflammation of the spine and the sacroiliac joints.
The global Ankylosing Spondylitis Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Ankylosing Spondylitis Drug market based on company, product type, end user and key regions.
This report studies the global market size of Ankylosing Spondylitis Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Ankylosing Spondylitis Drug in these regions.
This research report categorizes the global Ankylosing Spondylitis Drug market by top players/brands, region, type and end user. This report also studies the global Ankylosing Spondylitis Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amgen
Wyeth
Takeda
Centocor
Schering-Plough
Mitsubishi Tanabe
Abbott
Eisai
Pfizer
Johnson & Johnson
Market size by Product
Cimzia
Enbrel
Humira
Remicade
Simponi
Others
Market size by End User
Hospitals
Clinics
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Ankylosing Spondylitis Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Ankylosing Spondylitis Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Ankylosing Spondylitis Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Ankylosing Spondylitis Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Ankylosing Spondylitis Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Ankylosing Spondylitis Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Ankylosing Spondylitis Drug Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Ankylosing Spondylitis Drug Market Size Growth Rate by Product
- 1.4.2 Cimzia
- 1.4.3 Enbrel
- 1.4.4 Humira
- 1.4.5 Remicade
- 1.4.6 Simponi
- 1.4.7 Others
- 1.5 Market by End User
- 1.5.1 Global Ankylosing Spondylitis Drug Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Clinics
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Ankylosing Spondylitis Drug Market Size
- 2.1.1 Global Ankylosing Spondylitis Drug Revenue 2014-2025
- 2.1.2 Global Ankylosing Spondylitis Drug Sales 2014-2025
- 2.2 Ankylosing Spondylitis Drug Growth Rate by Regions
- 2.2.1 Global Ankylosing Spondylitis Drug Sales by Regions
- 2.2.2 Global Ankylosing Spondylitis Drug Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Ankylosing Spondylitis Drug Sales by Manufacturers
- 3.1.1 Ankylosing Spondylitis Drug Sales by Manufacturers
- 3.1.2 Ankylosing Spondylitis Drug Sales Market Share by Manufacturers
- 3.1.3 Global Ankylosing Spondylitis Drug Market Concentration Ratio (CR5 and HHI)
- 3.2 Ankylosing Spondylitis Drug Revenue by Manufacturers
- 3.2.1 Ankylosing Spondylitis Drug Revenue by Manufacturers (2014-2019)
- 3.2.2 Ankylosing Spondylitis Drug Revenue Share by Manufacturers (2014-2019)
- 3.3 Ankylosing Spondylitis Drug Price by Manufacturers
- 3.4 Ankylosing Spondylitis Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Ankylosing Spondylitis Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Ankylosing Spondylitis Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Ankylosing Spondylitis Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Ankylosing Spondylitis Drug Sales by Product
- 4.2 Global Ankylosing Spondylitis Drug Revenue by Product
- 4.3 Ankylosing Spondylitis Drug Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Ankylosing Spondylitis Drug Breakdown Data by End User
6 North America
- 6.1 North America Ankylosing Spondylitis Drug by Countries
- 6.1.1 North America Ankylosing Spondylitis Drug Sales by Countries
- 6.1.2 North America Ankylosing Spondylitis Drug Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Ankylosing Spondylitis Drug by Product
- 6.3 North America Ankylosing Spondylitis Drug by End User
7 Europe
- 7.1 Europe Ankylosing Spondylitis Drug by Countries
- 7.1.1 Europe Ankylosing Spondylitis Drug Sales by Countries
- 7.1.2 Europe Ankylosing Spondylitis Drug Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Ankylosing Spondylitis Drug by Product
- 7.3 Europe Ankylosing Spondylitis Drug by End User
8 Asia Pacific
- 8.1 Asia Pacific Ankylosing Spondylitis Drug by Countries
- 8.1.1 Asia Pacific Ankylosing Spondylitis Drug Sales by Countries
- 8.1.2 Asia Pacific Ankylosing Spondylitis Drug Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Ankylosing Spondylitis Drug by Product
- 8.3 Asia Pacific Ankylosing Spondylitis Drug by End User
9 Central & South America
- 9.1 Central & South America Ankylosing Spondylitis Drug by Countries
- 9.1.1 Central & South America Ankylosing Spondylitis Drug Sales by Countries
- 9.1.2 Central & South America Ankylosing Spondylitis Drug Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Ankylosing Spondylitis Drug by Product
- 9.3 Central & South America Ankylosing Spondylitis Drug by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Ankylosing Spondylitis Drug by Countries
- 10.1.1 Middle East and Africa Ankylosing Spondylitis Drug Sales by Countries
- 10.1.2 Middle East and Africa Ankylosing Spondylitis Drug Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Ankylosing Spondylitis Drug by Product
- 10.3 Middle East and Africa Ankylosing Spondylitis Drug by End User
11 Company Profiles
- 11.1 Amgen
- 11.1.1 Amgen Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Amgen Ankylosing Spondylitis Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Amgen Ankylosing Spondylitis Drug Products Offered
- 11.1.5 Amgen Recent Development
- 11.2 Wyeth
- 11.2.1 Wyeth Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Wyeth Ankylosing Spondylitis Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Wyeth Ankylosing Spondylitis Drug Products Offered
- 11.2.5 Wyeth Recent Development
- 11.3 Takeda
- 11.3.1 Takeda Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Takeda Ankylosing Spondylitis Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Takeda Ankylosing Spondylitis Drug Products Offered
- 11.3.5 Takeda Recent Development
- 11.4 Centocor
- 11.4.1 Centocor Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Centocor Ankylosing Spondylitis Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Centocor Ankylosing Spondylitis Drug Products Offered
- 11.4.5 Centocor Recent Development
- 11.5 Schering-Plough
- 11.5.1 Schering-Plough Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Schering-Plough Ankylosing Spondylitis Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Schering-Plough Ankylosing Spondylitis Drug Products Offered
- 11.5.5 Schering-Plough Recent Development
- 11.6 Mitsubishi Tanabe
- 11.6.1 Mitsubishi Tanabe Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Mitsubishi Tanabe Ankylosing Spondylitis Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Mitsubishi Tanabe Ankylosing Spondylitis Drug Products Offered
- 11.6.5 Mitsubishi Tanabe Recent Development
- 11.7 Abbott
- 11.7.1 Abbott Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Abbott Ankylosing Spondylitis Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Abbott Ankylosing Spondylitis Drug Products Offered
- 11.7.5 Abbott Recent Development
- 11.8 Eisai
- 11.8.1 Eisai Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Eisai Ankylosing Spondylitis Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Eisai Ankylosing Spondylitis Drug Products Offered
- 11.8.5 Eisai Recent Development
- 11.9 Pfizer
- 11.9.1 Pfizer Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Pfizer Ankylosing Spondylitis Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Pfizer Ankylosing Spondylitis Drug Products Offered
- 11.9.5 Pfizer Recent Development
- 11.10 Johnson & Johnson
- 11.10.1 Johnson & Johnson Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Johnson & Johnson Ankylosing Spondylitis Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Johnson & Johnson Ankylosing Spondylitis Drug Products Offered
- 11.10.5 Johnson & Johnson Recent Development
12 Future Forecast
- 12.1 Ankylosing Spondylitis Drug Market Forecast by Regions
- 12.1.1 Global Ankylosing Spondylitis Drug Sales Forecast by Regions 2019-2025
- 12.1.2 Global Ankylosing Spondylitis Drug Revenue Forecast by Regions 2019-2025
- 12.2 Ankylosing Spondylitis Drug Market Forecast by Product
- 12.2.1 Global Ankylosing Spondylitis Drug Sales Forecast by Product 2019-2025
- 12.2.2 Global Ankylosing Spondylitis Drug Revenue Forecast by Product 2019-2025
- 12.3 Ankylosing Spondylitis Drug Market Forecast by End User
- 12.4 North America Ankylosing Spondylitis Drug Forecast
- 12.5 Europe Ankylosing Spondylitis Drug Forecast
- 12.6 Asia Pacific Ankylosing Spondylitis Drug Forecast
- 12.7 Central & South America Ankylosing Spondylitis Drug Forecast
- 12.8 Middle East and Africa Ankylosing Spondylitis Drug Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Ankylosing Spondylitis Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Ankylosing Spondylitis Drug . Industry analysis & Market Report on Ankylosing Spondylitis Drug is a syndicated market report, published as Global Ankylosing Spondylitis Drug Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Ankylosing Spondylitis Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
